A low-profile copper intrauterine device that delivers long-acting contraception an
Project Number5R01AI150325-05
Former Number1R01AI150325-01
Contact PI/Project LeaderWOODROW, KIM A. Other PIs
Awardee OrganizationUNIVERSITY OF WASHINGTON
Description
Abstract Text
ABSTRACT
The dual impacts of the HIV/AIDS pandemic and unintended pregnancies constitute a major health burden for
women worldwide and justify the development of highly-effective next-generation multipurpose prevention
technologies (NGM) that combine safe, effective, and easily reversible long-acting contraception with HIV
prevention. Here, we propose to adapt a memory wire copper intrauterine device (IUD) frame as a platform for
intrauterine delivery of antiretroviral (AVR) drugs to provide user friendly HIV pre-exposure prophylaxis (PrEP)
and contraception. We propose to evaluate ARV drug delivery systems compatible with IUD delivery for duel-
protection up to three years. In Aim 1, we will formulate candidate antiviral drug/prodrug solid dispersions in
matrix, reservoir and electrospun drug delivery systems and integrate these into an existing copper IUD to
optimize drug loading, dissolution rate, chemical and functional stability, and stable integration with and
functional attributes of the IUD. We will then evaluate the safety and pharmacokinetic effects of intrauterine
delivery of candidate devices in baboons, and measure drug concentrations in the vagina, cervix, and
endometrium. Finally, in Aim 3 we will use the macaque model to evaluate the protective efficacy of the drug-
eluting delivery system for HIV pre-exposure prophylaxis against a repeated low-dose vaginal SHIV162P3
challenge.
Public Health Relevance Statement
PROJECT NARRATIVE
Female-controlled prevention methods against sexual HIV-1 transmission and pregnancy are critically needed.
Here, we propose to develop an innovative platform for long-acting HIV prevention and contraception by
integrating antiviral drug delivery onto an innovative shape-memory copper-containing intrauterine device. This
approach will empower and provide women with a multipurpose technology for effective control of their
reproductive health.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
605799469
UEI
HD1WMN6945W6
Project Start Date
16-September-2020
Project End Date
31-August-2025
Budget Start Date
01-September-2024
Budget End Date
31-August-2025
Project Funding Information for 2024
Total Funding
$733,984
Direct Costs
$603,767
Indirect Costs
$130,217
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$733,984
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI150325-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI150325-05
Patents
No Patents information available for 5R01AI150325-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI150325-05
Clinical Studies
No Clinical Studies information available for 5R01AI150325-05
News and More
Related News Releases
No news release information available for 5R01AI150325-05
History
No Historical information available for 5R01AI150325-05
Similar Projects
No Similar Projects information available for 5R01AI150325-05